Aktienanalyse zu Lexicon Pharmaceuticals Inc (LXRX)LXRXLexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals, Inc., is a biopharmaceutical company. The Company is engaged in research and development of drug candidates and the commercialization of the drug, INPEFA (sotagliflozin). INPEFA reduces the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, chronic kidney disease (CKD), and other cardiovascular risk factors. Sotagliflozin is an orally delivered small molecule drug candidate as a treatment for hypertrophic cardiomyopathy (HCM) and conducts the SONATA-HCM pivotal Phase 3 clinical trial of sotagliflozin in that indication. The Company develops pilavapadin, an orally delivered small molecule drug candidate, as a treatment for neuropathic pain. The Company also develops LX9851, an orally delivered small molecule drug candidate, for the treatment of obesity and associated cardiometabolic disorders. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Lexicon Pharmaceuticals (LXRX) is a good buy right now due to its recent milestone payment of $10 million from Novo Nordisk, contributing to a total of $75 million in milestone payments, indicating strong collaboration and growth potential. The current price of $2.29 is significantly below the analyst price target of $3.10, suggesting a potential upside of 35.4%. Additionally, the company has shown a remarkable year-to-date change of +100.88%, reflecting strong investor interest and optimism about its future prospects. However, the main risk is the high negative net income reported for Q2 2026 at -31.77 million USD, which highlights ongoing financial challenges that investors should monitor closely.

7 analysts cover LXRX: 4 rate it Buy, 3 Hold and 0 Sell. The average price target is 4.03.